within Pharmacolibrary.Drugs.ATC.L;

model L04AC07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.29 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 800 / 1000000,
    adminCount     = 1,
    Vd             = 0.0064,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Tocilizumab is a recombinant humanized monoclonal antibody that acts as an interleukin-6 receptor antagonist. It is approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, giant cell arteritis, and cytokine release syndrome, and it has been used during the COVID-19 pandemic for severe inflammatory responses. Tocilizumab is administered primarily via intravenous infusion or subcutaneous injection.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters based on two-compartment model in patients with rheumatoid arthritis after a single intravenous dose. The data are pooled from clinical studies in adult human subjects.</p><h4>References</h4><ol><li><p>Paccaly, AJ, Kovalenko, P, Parrino, J, Boyapati, A, Xu, C, van Hoogstraten, H, Ishii, T, Davis, JD, &amp; DiCioccio, AT (2021). Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single-Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate. <i>Journal of clinical pharmacology</i> 61(1) 90–104. DOI:<a href=&quot;https://doi.org/10.1002/jcph.1703&quot;>10.1002/jcph.1703</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32726514/&quot;>https://pubmed.ncbi.nlm.nih.gov/32726514</a></p></li><li><p>Tomaszewska-Kiecana, M, Ullmann, M, Petit-Frere, C, Monnet, J, Dagres, C, &amp; Illes, A (2023). Pharmacokinetics of a proposed tocilizumab biosimilar (MSB11456) versus US-licensed tocilizumab: results of a randomized, double-blind, single-intravenous dose study in healthy adults. <i>Expert review of clinical immunology</i> 19(4) 439–446. DOI:<a href=&quot;https://doi.org/10.1080/1744666X.2023.2174104&quot;>10.1080/1744666X.2023.2174104</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36715299/&quot;>https://pubmed.ncbi.nlm.nih.gov/36715299</a></p></li><li><p>Xu, C, Rafique, A, Potocky, T, Paccaly, A, Nolain, P, Lu, Q, Iglesias-Rodriguez, M, St John, G, Nivens, MC, Kanamaluru, V, Fairhurst, J, Ishii, T, Maldonado, R, Choy, E, &amp; Emery, P (2021). Differential Binding of Sarilumab and Tocilizumab to IL-6Rα and Effects of Receptor Occupancy on Clinical Parameters. <i>Journal of clinical pharmacology</i> 61(5) 714–724. DOI:<a href=&quot;https://doi.org/10.1002/jcph.1795&quot;>10.1002/jcph.1795</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33314148/&quot;>https://pubmed.ncbi.nlm.nih.gov/33314148</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AC07;
